

Victoria Watson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12193071/publications.pdf>

Version: 2024-02-01

11
papers

458
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

632
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1455-1465.	2.3	116
2	Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 590-596.	2.1	62
3	Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. <i>Aids</i> , 2009, 23, 2537-2540.	2.2	53
4	Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. <i>Journal of NeuroVirology</i> , 2016, 22, 852-860.	2.1	48
5	Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. <i>New England Journal of Medicine</i> , 2020, 383, 2242-2254.	27.0	34
6	Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 450-457.	2.1	31
7	Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1642-1647.	3.0	29
8	Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 222-227.	2.1	28
9	CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 206-212.	3.0	28
10	Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 72-75.	3.2	24
11	Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 885-889.	3.0	5